Atopic Dermatitis
Conditions
Interventions
investigational material(s)
Generic name etc : Experimental: Baricitinib
INN of investigational material :
Therapeutic category code : 449 Other antiallergic agents
Dosage and Administration for Inve
Sponsors
Eli Lilly Japan K.K.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: *Have moderate-to-severe Atopic Dermatitis (AD), as determined by all of the following: a. EASI of 12 or more b. Greater than or equal to 10% of body surface area involvement c. Diagnosed with AD at least 2 years prior *Have a history of inadequate clinical response to other eczema treatments
Exclusion criteria
Exclusion criteria: *Females who are pregnant or nursing *Participants who do not agree to use adequate contraception *Are currently experiencing or have a history of: -Skin conditions such as psoriasis or lupus erythematosus -Skin disease that requires frequent hospitalizations or intravenous treatment -Compromised immunity *Serious illness that could interfere with study participation, or a clinically important deviation in physical examination, vital sign measurements, electrocardiograms, or abnormalities on laboratory tests *Currently experiencing or have a history of: -Active or latent Tuberculosis or specific immunity disorders and infections -Malignancy or lymphoproliferative diseases -Human Immunodeficiency Virus (HIV) -Hepatitis B, Hepatitis C, or chronic liver disease *Have received certain types of vaccinations
Outcome results
None listed